Daunorubicin/Cytarabine Liposome: A Review in Acute Myeloid Leukaemia

VYXEOS(™) is a liposomal-encapsulated formulation of daunorubicin and cytarabine delivering a fixed, synergistic 1:5 molar ratio (hereafter referred to as daunorubicin/cytarabine liposome). Daunorubicin/cytarabine liposome is approved in several countries worldwide for the treatment of adults with t...

Descripción completa

Detalles Bibliográficos
Autor principal: Blair, Hannah A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Adis Drug Evaluation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6314217/
https://www.ncbi.nlm.nih.gov/pubmed/30511323
http://dx.doi.org/10.1007/s40265-018-1022-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6314217/
https://www.ncbi.nlm.nih.gov/pubmed/30511323
http://dx.doi.org/10.1007/s40265-018-1022-3

Ejemplares similares